Drugs / Paclitaxel for Injection (albumin bound)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04405505 Comparator | Jun 2020 → Jul 2022 | triple-negative breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel for Injection (albumin bound) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04405505 ↗ |
| Route | Intravenous | “100mg / m2 administered intravenously (IV)” NCT04405505 ↗ |